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ABSTRACT 
Background: SGLT-2 inhibitor has been shown to confer significant cardiovascular 
(CV) risk reduction in T2DM patients with ischaemic heart disease. However, the 
mechanism remains unclear. Endothelial dysfunction is a recognized independent 
predictor of cardiovascular events particularly in T2DM. It is effectively assessed via the 
measurements of flow-mediated vasodilatation (FMD). 
Aims: This study therefore aimed to demonstrate the effect of dapagliflozin on 
endothelial dysfunction as a possible mechanism in CV risk reductions in high-risk 
T2DM subjects. 
Methods: This was a prospective, double-blinds, placebo-controlled, clinical trial on 
T2DM patients with underlying ischaemic heart disease who were receiving metformin 
and insulin therapy (n=81). Subjects were randomised to receive 12-weeks therapy of 
either dapagliflozin (n=40) or placebo (n=41). Subjects underwent an endothelial function 
examination measured by AFMD and ANMD and surrogate markers; ICAM-1, eNOS, 
hsCRP and Lp(a) of according to the standard protocols. Glycaemic and lipid profiles 
were also measured as well as metabolic and hemodynamic changes. 
Results: After 12 weeks of therapy, dapagliflozin group demonstrated significantly 
bigger reductions of HbAlc and fasting blood sugar (FBS) compared to the placebo 
group (AHbAlc -0.16±1.25 vs. -0.83±1.47, p=0.042 and AFBS -1.90±4.40 vs -0.73±4.55, 
p=0.015, respectively). There is improvement in ICAM-1 level in dapagliflozin group 
which showed improvement in endothelial inflammation (AICAM-1, dapagliflozin group 
vs placebo group, -83.9± 205.9ng/mL : p<0.02 vs -11.0±169.1 ng/mL p= 0.699) . Albeit 
no statistical significance, there seemed to be a worsening of AFMD within the placebo 
group whilst the active group had similar values. Univariate correlation analysis revealed 
a significant negative correlation between HbAlc and AFMD within the active group (r= 
-0.31, p= 0.02) which was not seen within the placebo group. 
Conclusion: A 12-week therapy with dapagliflozin, in addition to insulin and metformin, 
resulted in significant reductions in HbAlc and FBS, which was further associated with 
improvement in endothelial dysfunction as measured by FMD and ICAM-1. Preservation 
of endothelial function within the dapagliflozin group could potentially attenuate 
progression of atherosclerosis in a group of patients with high plaque burden. 
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